Table 1 Current FDA-approved immune checkpoint inhibitors (ICIs)
From: Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons
Agent | Target IC | Approved conditions |
|---|---|---|
Ipilimumab | CTLA-4 | Melanoma, MSI-H/dMMR colorectal cancer (CRC), renal cell carcinoma (RCC) (in combination with nivolumab) |
Nivolumab | PD-1 | MSI-H or dMMR colorectal cancer (CRC), head and neck squamous cell carcinomas (HNSCC), hepatocellular carcinoma (HCC), melanoma, Classic Hodgkin lymphoma (cHL), non-small-cell lung carcinoma (NSCLC), renal cell carcinoma (RCC), urothelial cancer, small-cell lung carcinoma (c-SCLC) |
Pembrolizumab | PD-1 | Cervical cancer, gastric cancer, head and neck squamous cell carcinomas (HNSCC), hepatocellular carcinoma (HCC), Classic Hodgkin lymphoma (cHL), melanoma, Merkel cell carcinoma (MCC), MSI-H or dMMR colorectal cancer (CRC), non-small-cell lung carcinoma (NSCLC), diffuse large B-cell lymphoma (DLBCL), urothelial cancer |
Cemiplimab | PD-1 | Cutaneous squamous cell carcinoma (cSCC) |
Atezolizumab | PD-L1 | Non-small-cell lung carcinoma (NSCLC), urothelial cancer |
Avelumab | PD-L1 | Merkel cell carcinoma (MCC), urothelial cancer |
Durvalumab | PD-L1 | Non-small-cell lung carcinoma (NSCLC), urothelial cancer |